J Pediatr Infect Dis 2018; 13(02): 153-168
DOI: 10.1055/s-0037-1607234
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents

Silvia S. Chiang
1  Department of Pediatrics, Alpert Medical School of Brown University, Providence, Rhode Island, United States
2  Center for International Health Research, Rhode Island Hospital, Providence, Rhode Island, United States
,
Jennifer J. Furin
3  Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts United States
› Author Affiliations
Funding Silvia S. Chiang is supported by the U.S. National Institutes of Health (T32 DA013911).
Further Information

Publication History

17 March 2017

02 June 2017

Publication Date:
15 October 2017 (eFirst)

Abstract

Although tens of thousands of children and adolescents become sick with multidrug-resistant tuberculosis (MDR-TB) each year, fewer than 1,500 cases documenting treatment have been reported in the literature. Children treated for MDR-TB tend to have excellent clinical outcomes, but they suffer from the adverse events associated with current management strategies. This article will review the recommendations, evidence base, and future directions for MDR-TB therapy in children and adolescents.